Lipocine Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
LPCN$1.72+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA |
LIPOCINE INC.
INDEX TO FINANCIAL STATEMENTS
| Page | |
|---|---|
| Audited Financial Statements of Lipocine Inc. for the Years ended December 31, 2024 and 2023 | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 270) | 65 |
| Consolidated Balance Sheets | 66 |
| Consolidated Statements of Operations and Comprehensive Loss | 67 |
| Consolidated Statements of Changes in Stockholders’ Equity | 68 |
| Consolidated Statements of Cash Flows | 69 |
| Notes to Consolidated Financial Statements | 70 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.